After targeting Indian IT majors with the H-1B visa fee hike, US President Donald Trump has now turned his attention to the pharmaceutical sector, imposing a 100% tariff on branded and patented drugs starting October 1, 2025.

Pharmaceutical shares came under heavy selling pressure on Friday following the announcement, raising concerns over broader trade disruptions. The Nifty Pharma index dropped 2.40% in morning trade, with all 20 of its constituents in the red.

While most Indian pharma companies derive the bulk of their revenues from generics, the tariff rattled investor sentiment, pushing Sun Pharma, Cipla, and Dr. Reddy’s shares down by up to 5%.

With 30–47% of their revenues linked to the US market, analysts are evaluating which companies’ balance sheets could be hit hardest if Tru

See Full Page